QURE Stock Forecast: uniQure NV Price Predictions for 2026-2027
The median 12-month analyst price target for uniQure NV is $60. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores uniQure NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (88): The business earns solid, repeatable profits on what it owns.
Volatility (11): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
QURE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on QURE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 4 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $80 → $65 |
| 15 Oct 2026 | UBS | Assumes | Buy | $27 → $48 |
| 5 Oct 2026 | Barclays | Downgrade | Equal-Weight | $60 → $28 |
| 2 Oct 2026 | RBC Capital | Maintains | Outperform | $65 → $48 |
| 30 Sept 2026 | Goldman Sachs | Maintains | Neutral | $46 → $31 |
| 2 Sept 2026 | William Blair | Reinstates | Outperform | — |
| 30 July 2026 | Barclays | Maintains | Overweight | $65 → $60 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | $60 → $75 |
| 30 July 2026 | Wolfe Research | Upgrade | Outperform | $65 |
| 29 June 2026 | HC Wainwright & Co. | Maintains | Buy | $50 → $80 |
| 25 June 2026 | Mizuho | Maintains | Outperform | $35 → $68 |
| 18 June 2026 | Barclays | Upgrade | Overweight | — |
| 18 June 2026 | Goldman Sachs | Maintains | Neutral | — |
| 18 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 18 June 2026 | RBC Capital | Maintains | Outperform | — |
| 6 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Apr 2026 | Chardan Capital | Maintains | Buy | — |
| 20 Apr 2026 | Goldman Sachs | Maintains | Neutral | — |
| 23 Mar 2026 | Barclays | Maintains | Equal-Weight | — |
| 11 Mar 2026 | Mizuho | Upgrade | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for QURE.
This page is one stock. Monday covers all of them.
QURE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
QURE vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, uniQure NV returned −30.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
QURE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 67.3×
- Price / book
- 4.6×
- EV / EBITDA
- —
Cheaper than 4% of US stocks
Cheaper than 20% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 94.0%
- Operating margin
- —
- Net margin
- —
Higher than 98% of US stocks
- Return on equity
- −89.0%
- Return on assets
- −13.7%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 24% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
uniQure NV has a market value of $1.4B and an enterprise value of $1.2B.
Revenue in the twelve months to 30 June 2026: $18.7M. The latest quarter grew 11.0% year on year.
Net income over the same four quarters: −$252.2M, a −1350.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$161.5M.
uniQure NV employs 221 people — $84K of revenue per employee.
Data provided by Twelve Data
QURE and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at QURE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own uniQure NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about QURE
What is the QURE stock price forecast for 2026-2027?
The median 12-month analyst price target for uniQure NV is $60, with estimates ranging from $27 to $93. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is QURE stock a buy right now?
Of the 13 analysts covering uniQure NV, 11 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks uniQure NV 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank QURE?
As at 21 Nov 2026, uniQure NV ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (88 of 100).
Will QURE stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts is $60, and Ticker Nerd's factor model ranks uniQure NV 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the QURE stock forecast for 2030?
No analyst covering uniQure NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QURE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $93 over the next 12 months.
How has QURE stock performed over the past year?
uniQure NV returned -30.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does uniQure NV do?
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease.
About uniQure NV.
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease. The company uses an adeno-associated virus (AAV) platform to develop one-time treatments designed to address the underlying cause of disease, with activities spanning research, development, manufacturing, and commercialization. Headquartered in Amsterdam, the Netherlands, uniQure serves the rare-disease and specialty therapeutic markets through both proprietary programs and selected partnerships.
CEO Mr. Matthew Craig Kapusta CPA · 221 employees · Netherlands · https://www.uniqure.com